Dermapharm Holding SE AI Price Prediction

With EPS of €2.15 and a PE ratio of 21.65, the market is pricing Dermapharm at a moderate premium to earnings, suggesting expectations of steady but not hyper‑growth. The valuation appears reasonable for a profitable specialty pharma company, but without additional data on revenue and margin trends, it is difficult to justify a clearly bullish or bearish stance. Overall, the earnings profile looks solid yet not obviously mispriced.

• EPS of €2.15 combined with a share price of €46.55 implies a PE of 21.65, which is in a mid‑20s range typical for profitable, moderately growing healthcare names in Europe.
• The PE level suggests investors expect continued earnings stability or modest growth rather than deep distress or aggressive growth re‑rating potential.
• Lack of granular data on revenue growth, gross margin, and net margin trends prevents a stronger view; current metrics indicate a healthy, profitable business but not an obvious bargain or bubble.

The stock trades at €46.55, roughly 19–20% above its 200‑day moving average of €38.91, indicating a generally positive longer‑term trend despite a recent 7.8% pullback over the last month. Trading well above the 200‑day average usually signals underlying strength, but the recent decline hints at some short‑term profit‑taking or sentiment cooling. Without an explicit RSI reading, the technical picture skews to constructive but not strongly bullish.

• Price at €46.55 vs. a 200‑day moving average of €38.91 indicates the stock is trading materially above its longer‑term trend, a classically positive technical signal.
• A 7.8% drop over the last month suggests short‑term weakness or consolidation after a prior up‑move, rather than a clear breakdown given the still‑elevated level vs. the 200‑day MA.
• In the absence of a specific RSI value, the combination of a pullback from higher levels but price still above the 200‑day MA points to neutral momentum: neither clearly overbought nor structurally broken.

Alternative data for Dermapharm Holding SE is modest in scale and offers limited directional conviction. Web traffic is low at an estimated 3,980 monthly visitors, and social media presence is small but slowly growing, suggesting a conservative digital footprint rather than strong brand‑driven retail momentum. A 100% month‑over‑month increase to 2 job openings hints at some incremental hiring, but the absolute numbers are too small to be a strong growth signal.

• Estimated web traffic of 3,980 visitors per month is relatively low, indicating limited online engagement; there is no clear evidence of a surge in customer or investor interest from this channel.
• Social media presence is small (26 YouTube subscribers, up 4% in 90 days; 2,585 LinkedIn followers), pointing to a low retail/consumer visibility profile but steady incremental growth rather than deterioration.
• Job postings increased 100% month over month to 2 openings, which is directionally positive but numerically insignificant, suggesting only marginal expansion rather than a large growth or restructuring phase.

Dermapharm Holding SE appears to be a solidly profitable company trading at a moderate earnings multiple, with a stock price still above its long‑term trend despite a recent pullback. Alternative data signals are small in scale and do not strongly reinforce either a bullish or bearish narrative. Overall, the balance of fundamentals, valuation, and technicals supports a neutral view at current levels.

• Earnings and valuation (EPS €2.15, PE 21.65) indicate a reasonably priced, profitable pharma name without a clear mispricing signal.
• Technicals show price comfortably above the 200‑day moving average but recently correcting, consistent with consolidation rather than a strong new trend in either direction.